Advances in Cancer and Glycosylation

A special issue of Biomolecules (ISSN 2218-273X). This special issue belongs to the section "Molecular Medicine".

Deadline for manuscript submissions: closed (30 April 2025) | Viewed by 1549

Special Issue Editor


E-Mail Website
Guest Editor
Department of Biomedical and Molecular Sciences, Queen's University, Kingston, ON K7L 3N6, Canada
Interests: the role of glycosylation in receptor activation; TOLL-like; nerve growth factor Trk; EGFR and insulin receptors
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Over 3-5 decades, altered sialylation of tumor cell surface glycoproteins has been described to be highly associated with the metastatic phenotype of cancer. In an effort to understand this metastatic behavior in relation to altered sialic acid, tumor cell surfaces have been extensively analyzed in the past and present for melanomas, T-cell hybridomas, methylcholanthrene A-induced T-cell lymphoma sublines, B16F10 melanoma cells, metastatic variants, breast, pancreatic, and other cancers. It is now accepted that aberrant sialylation in cancer cells is at least one of the characteristic features associated with the metastatic potential of cancer cells. Interference with sialic acid expression in cancer cells is the current target in preventing metastasis. In particular, desialylation of cancer cells by overexpressing human sialidases has been reported to inhibit metastases in murine metastasis models.

This Special Issue aims to highlight aspects of protein glycosylation in all cancer. Contributions (research articles, reviews, communications) that cover the structural elucidation, function, biosynthesis, or degradation of glycans and the characterization of enzymes involved in cancer processes are very welcome, as are papers dealing with methodical improvements for the analysis of glycans or enzymes recognizing carbohydrate structures.

Prof. Dr. Myron R. Szewczuk
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Biomolecules is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • glycosylation
  • glycobiology
  • N-glycans
  • O-glycans
  • glycosyltransferases
  • glycosidases

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • e-Book format: Special Issues with more than 10 articles can be published as dedicated e-books, ensuring wide and rapid dissemination.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Review

21 pages, 1649 KiB  
Review
The Oncoprotein Mucin 1 in Pancreatic Cancer Onset and Progression: Potential Clinical Implications
by Rosalia Dieli, Rosa Lioy, Fabiana Crispo, Nicoletta Cascelli, Mara Martinelli, Rosa Lerose, Donatella Telesca, Maria Rita Milella, Marco Colella, Simona Loperte and Carmela Mazzoccoli
Biomolecules 2025, 15(2), 275; https://doi.org/10.3390/biom15020275 - 13 Feb 2025
Viewed by 1070
Abstract
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by poor prognosis, therapeutic resistance, and frequent recurrence. Current therapeutic options for PDAC include surgery, radiotherapy, immunological and targeted approaches. However, all these therapies provide only a slight improvement in patient survival. Consequently, [...] Read more.
Pancreatic ductal adenocarcinoma (PDAC) is a highly lethal malignancy characterized by poor prognosis, therapeutic resistance, and frequent recurrence. Current therapeutic options for PDAC include surgery, radiotherapy, immunological and targeted approaches. However, all these therapies provide only a slight improvement in patient survival. Consequently, the discovery of novel specific targets is becoming a priority to develop more effective treatments for PDAC. Mucin 1 (MUC1), a transmembrane glycoprotein, is aberrantly glycosylated and frequently overexpressed in pancreatic cancer. Recent studies highlighted the role of this oncoprotein in pancreatic carcinogenesis and its involvement in the acquisition of typical aggressive features of PDAC, like local invasion, metastases, and drug resistance. This review explores the mechanisms by which MUC1 contributes to cancer onset and progression, with a focus on its potential role as a biomarker and novel therapeutic target for pancreatic adenocarcinoma treatment. Full article
(This article belongs to the Special Issue Advances in Cancer and Glycosylation)
Show Figures

Graphical abstract

Back to TopTop